Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
RLMD Quote, Financials, Valuation and Earnings
Last price:
$4.05
Seasonality move
:
24.86%
Day range:
$3.97 - $4.17
52-week range:
$0.24 - $5.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
31.22x
Volume:
227.4K
Avg. volume:
593.2K
1-year change:
1266.1%
Market cap:
$295.5M
Revenue:
--
EPS (TTM):
-$1.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -- | -- | -- | $9.67 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.53 |
|
ACLX
Arcellx, Inc.
|
$13.4M | -$1.05 | -17.12% | -2.29% | $110.43 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 31.89% | 267.32% | $14.50 |
|
IVVD
Invivyd, Inc.
|
$15.5M | -$0.10 | 49.95% | -35.02% | $10.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
$4.03 | $9.67 | $295.5M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.73 | $31.53 | $4.2B | 15.91x | $0.00 | 0% | 3.98x |
|
ACLX
Arcellx, Inc.
|
$113.75 | $110.43 | $6.6B | -- | $0.00 | 0% | 176.15x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$329.35 | $457.00 | $43.7B | 145.92x | $0.00 | 0% | 11.84x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.36 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.00x |
|
IVVD
Invivyd, Inc.
|
$1.61 | $10.00 | $375.3M | -- | $0.00 | 0% | 4.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
-- | 6.678 | -- | 2.68x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ACLX
Arcellx, Inc.
|
10.52% | 0.923 | 1.09% | 3.90x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -0.293 | 10.04% | 1.72x |
|
IVVD
Invivyd, Inc.
|
2.8% | -0.370 | 1.14% | 2.13x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -$10.3M | -214.4% | -214.4% | -- | -$6.7M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ACLX
Arcellx, Inc.
|
$3.1M | -$61.8M | -44.21% | -49.8% | -1248.25% | -$49.5M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
IVVD
Invivyd, Inc.
|
$11.6M | -$11M | -85.47% | -87.85% | -83.96% | -$8.3M |
Relmada Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RLMD or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of 25.76%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About RLMD or ACAD?
Relmada Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 139.87%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.53 which suggests that it could grow by 27.48%. Given that Relmada Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.3 0 0 ACADACADIA Pharmaceuticals, Inc.10 5 1 -
Is RLMD or ACAD More Risky?
Relmada Therapeutics, Inc. has a beta of 0.766, which suggesting that the stock is 23.406% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock RLMD or ACAD?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or ACAD?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 3.98x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M ACADACADIA Pharmaceuticals, Inc.3.98x 15.91x $278.6M $71.8M
-
Which has Higher Returns RLMD or ACLX?
Arcellx, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of -1127.12%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Arcellx, Inc.'s return on equity of -49.8%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M ACLXArcellx, Inc.62.76% -$0.99 $492.6M -
What do Analysts Say About RLMD or ACLX?
Relmada Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 139.87%. On the other hand Arcellx, Inc. has an analysts' consensus of $110.43 which suggests that it could fall by -2.92%. Given that Relmada Therapeutics, Inc. has higher upside potential than Arcellx, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Arcellx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.3 0 0 ACLXArcellx, Inc.7 11 0 -
Is RLMD or ACLX More Risky?
Relmada Therapeutics, Inc. has a beta of 0.766, which suggesting that the stock is 23.406% less volatile than S&P 500. In comparison Arcellx, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RLMD or ACLX?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcellx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Arcellx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or ACLX?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Arcellx, Inc. quarterly revenues of $4.9M. Relmada Therapeutics, Inc.'s net income of -$10.1M is higher than Arcellx, Inc.'s net income of -$55.8M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcellx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 176.15x for Arcellx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M ACLXArcellx, Inc.176.15x -- $4.9M -$55.8M
-
Which has Higher Returns RLMD or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of 16.99%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About RLMD or ALNY?
Relmada Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 139.87%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 38.76%. Given that Relmada Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.3 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is RLMD or ALNY More Risky?
Relmada Therapeutics, Inc. has a beta of 0.766, which suggesting that the stock is 23.406% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock RLMD or ALNY?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or ALNY?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 145.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 11.84x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M ALNYAlnylam Pharmaceuticals, Inc.11.84x 145.92x $1.1B $186.4M
-
Which has Higher Returns RLMD or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of 0.91%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About RLMD or FOLD?
Relmada Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 139.87%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.98%. Given that Relmada Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.3 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is RLMD or FOLD More Risky?
Relmada Therapeutics, Inc. has a beta of 0.766, which suggesting that the stock is 23.406% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock RLMD or FOLD?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or FOLD?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 7.00x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M FOLDAmicus Therapeutics, Inc.7.00x -- $185.2M $1.7M
-
Which has Higher Returns RLMD or IVVD?
Invivyd, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of -79.75%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Invivyd, Inc.'s return on equity of -87.85%.
Company Gross Margin Earnings Per Share Invested Capital RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M IVVDInvivyd, Inc.88.43% -$0.06 $95.7M -
What do Analysts Say About RLMD or IVVD?
Relmada Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 139.87%. On the other hand Invivyd, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 521.12%. Given that Invivyd, Inc. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Relmada Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RLMDRelmada Therapeutics, Inc.3 0 0 IVVDInvivyd, Inc.3 1 0 -
Is RLMD or IVVD More Risky?
Relmada Therapeutics, Inc. has a beta of 0.766, which suggesting that the stock is 23.406% less volatile than S&P 500. In comparison Invivyd, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RLMD or IVVD?
Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Invivyd, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RLMD or IVVD?
Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Invivyd, Inc. quarterly revenues of $13.1M. Relmada Therapeutics, Inc.'s net income of -$10.1M is higher than Invivyd, Inc.'s net income of -$10.5M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Invivyd, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 4.26x for Invivyd, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M IVVDInvivyd, Inc.4.26x -- $13.1M -$10.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Sell
48
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
ACLX alert for Feb 24
Arcellx, Inc. [ACLX] is up 77.43% over the past day.
Buy
73
HYMC alert for Feb 24
Hycroft Mining Holding Corp. [HYMC] is up 2.34% over the past day.
Sell
39
SCL alert for Feb 24
Stepan Co. [SCL] is down 20.6% over the past day.
